Insight into EMERALD Study Design by Resolution Therapeutics

Resolution Therapeutics Reveals EMERALD Study Design

Resolution Therapeutics Ltd, a pioneering biopharmaceutical company, is at the forefront of innovation with its Regenerative Macrophage Therapy. The company has announced an exciting development regarding its EMERALD Phase I/II clinical trial, which focuses on utilizing RTX001 in the treatment of patients with end-stage liver disease. Chief Investigator, Professor Jonathan Fallowfield, is set to present the comprehensive study design at the British Association for the Study of the Liver (BASL) annual meeting in 2025.

Overview of the EMERALD Study

The EMERALD study is a significant multicenter Phase I/II clinical trial aimed at evaluating the safety and efficacy of RTX001. This innovative therapy is designed for patients suffering from advanced liver disease. A notable milestone for the study was the successful dosing of the first patient at the Royal Infirmary of Edinburgh, marking a key achievement for the clinical team and participants alike.

Initial Findings and Presentation Details

Professor Fallowfield, an authority in Translational Liver Research, will present a detailed poster on the study design, including critical insights into the trial's structure and expected outcomes. The study is characterized as a first-in-human, single-arm, open-label trial that aims to provide valuable data on the therapeutic potential of RTX001.

Poster Presentation Overview

Title: An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of RTX001 Autologous Macrophages in Patients with Liver Cirrhosis and Hepatic Decompensation (EMERALD)
Paper Reference: P68
Presenting Author: Professor Jonathan Fallowfield, University of Edinburgh
Date/Time: 8 October 2025, 6:00pm – 8:00pm BST

Recruitment and Study Objectives

The EMERALD study is fully open to recruitment, with a projected enrollment of up to 25 patients across various leading hepatology centers in the UK and Spain. This inclusiveness is designed to ensure robust data collection and diverse patient representation.

Expert Commentary on the Study

Dr. Clifford Brass, Chief Medical Officer at Resolution Therapeutics, emphasized the groundbreaking nature of this study, stating, "EMERALD represents the first exploration of engineered Regenerative Macrophage Therapy in patients with severe liver fibrosis. We are excited to present the study design at BASL and begin recruitment, providing hope to patients with limited therapeutic options."

Conference Participation

Dr. Faisal Sheikh, the medical director of Resolution Therapeutics, will also be present at the conference. Attendees interested in discussing the EMERALD study or learning more about the innovative therapies being developed are encouraged to reach out for a meeting.

Advancements in Regenerative Macrophage Therapy

Through its extensive research and development efforts, Resolution Therapeutics is committed to advancing regenerative medicine specifically targeting inflammatory and fibrotic diseases like end-stage liver disease. The company's lead product, RTX001, is engineered to enhance the natural regenerative capabilities of macrophages, aiming to deliver superior efficacy and patient outcomes.

About RTX001

RTX001 represents the forefront of therapeutic innovation, showcasing engineered autologous macrophages designed to exert enhanced anti-fibrotic and anti-inflammatory effects. This novel approach aims to transform patient care in liver diseases, with the EMERALD study serving as a critical vehicle for identifying its effectiveness.

Commitment to Patient Care

Beyond liver disease, Resolution Therapeutics is exploring applications for RTX001 and its regenerative platform in other conditions, including graft-vs-host disease (GVHD) and various forms of lung fibrosis. This broad vision positions the company as a key player in regenerative therapies.

About the British Association for the Study of the Liver (BASL)

The BASL serves as the premier national association for hepatology in the UK, aiming to elevate liver health through research, education, and collaboration. The association represents a diverse community of healthcare professionals united in the mission to enhance liver-related knowledge and care standards.

Frequently Asked Questions

What is the EMERALD study?

The EMERALD study is a Phase I/II clinical trial assessing the safety and efficacy of RTX001 in patients with end-stage liver disease.

Who is the Chief Investigator for EMERALD?

Professor Jonathan Fallowfield, Chair of Translational Liver Research at the University of Edinburgh, is the Chief Investigator guiding the EMERALD study.

When will the EMERALD study be presented?

The study design will be presented at the BASL annual meeting on October 8, 2025.

Where will the study take place?

The EMERALD study is being conducted in leading hepatology centers across the UK and Spain.

What outcomes does RTX001 aim to improve?

RTX001 is designed to enhance regenerative capabilities for better treatment outcomes in patients with liver diseases.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.